Drug Profile
ARCT 810
Alternative Names: ARCT-810; LUNAR-OTCLatest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Arcturus Therapeutics
- Class RNA
- Mechanism of Action Ornithine carbamoyltransferase expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ornithine carbamoyltransferase deficiency disease
Most Recent Events
- 07 Mar 2024 Arcturus Therapeutics completes enrollment in a phase-I clinical trials in Ornithine carbamoyltransferase deficiency disease (Treatment-experienced) in USA (IV)(NCT04442347)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Ornithine-carbamoyltransferase-deficiency-disease(Treatment-experienced) in USA (IV, Injection)
- 07 Aug 2023 Arcturus Therapeutics completes enrollment in its phase I clinical trials in Ornithine carbamoyltransferase deficiency disease (Treatment-experienced) in USA (IV)